Compare RTX & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | AZN |
|---|---|---|
| Founded | 1934 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.3B | 316.4B |
| IPO Year | 1994 | N/A |
| Metric | RTX | AZN |
|---|---|---|
| Price | $172.65 | $188.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $204.25 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 1.8M |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | 1.52% | ★ 1.66% |
| EPS Growth | ★ 39.72 | N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $80,738,000,000.00 | N/A |
| Revenue This Year | $6.50 | $10.34 |
| Revenue Next Year | $6.71 | $6.43 |
| P/E Ratio | $118.77 | ★ $31.91 |
| Revenue Growth | ★ 17.15 | N/A |
| 52 Week Low | $123.60 | $66.16 |
| 52 Week High | $214.50 | $212.71 |
| Indicator | RTX | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 23.11 | 40.32 |
| Support Level | $166.74 | $182.39 |
| Resistance Level | $180.66 | $209.98 |
| Average True Range (ATR) | 5.10 | 3.24 |
| MACD | -2.62 | -1.98 |
| Stochastic Oscillator | 0.59 | 7.52 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.